Does a Japan-specific rivaroxaban dose demonstrate safety compared to warfarin in Japanese patients with atrial fibrillation?
A Japan-specific dose of rivaroxaban is safe in Japanese patients with atrial fibrillation, supporting the applicability of global ROCKET AF results to this population.
J-ROCKET AF demonstrated the safety of a Japan-specific rivaroxaban dose and supports bridging the global ROCKET AF results into Japanese clinical practice.
Hori et al. (Sun,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: